Phase II Trial of Becotatug Vedotin with Tislelizumab and Lenvatinib in Advanced ESCC
A Phase II trial is underway to evaluate the combination of Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib in patients with advanced ESCC post first-line treatment failure.
Phase II
Oncology / Esophageal Squamous Cell Carcinoma
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing Phase II trial for Becotatug Vedotin in combination with Tislelizumab and Lenvatinib addresses a critical gap in treatment options for advanced ESCC after first-line therapy failure. Success in this trial could reshape treatment paradigms and influence future clinical guidelines, making it a significant development for oncology strategy teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the trial's primary endpoint results for objective response rate and subsequent secondary endpoints, as well as any updates on patient recruitment and safety data.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.